The three-stage process of coagulation is complex, involving many di?erent substances. There are two cascading pathways of biochemical reactions for activating coagulation of blood. The extrinsic pathway is the main physiological mechanism, which is triggered when blood vessels are damaged, usually by trauma or surgery. The intrinsic pathway is activated by internal disruption of the wall of a blood vessel. The basic pattern is broadly the same for both and is summarised simply as follows:
prothrombin + calcium + thromboplastin
thrombin + ?brinogen
?brin
Prothrombin and calcium are normally present in the blood. Thromboplastin is an enzyme which is normally found in the blood platelets and in tissue cells. When bleeding occurs from a blood vessel, there is always some damage to tissue cells and to the blood platelets. As a result of this damage, thromboplastin is released and comes into contact with the prothrombin and calcium in the blood. In the presence of thromboplastin and calcium, prothrombin is converted into thrombin, which in turn interacts with ?brinogen – a protein always present in the blood – to form ?brin. Fibrin consists of needle-shaped crystals which, with the assistance of the blood platelets, form a ?ne network in which the blood corpuscles become enmeshed. This meshwork, or CLOT as it is known, gradually retracts until it forms a tight mass which, unless the tissue injury is very severe or a major artery has been damaged, prevents any further bleeding. It will thus be seen that clotting, or coagulation, does not occur in the healthy blood vessel because there is no thromboplastin present. There is now evidence suggesting that there is an anti-thrombin substance present in the blood in small amounts, and that this substance antagonises any small amounts of thrombin that may be formed as a result of small amounts of thromboplastin being released.
The clotting or coagulation time is the time taken for blood to clot and can be measured under controlled conditions to ensure that it is normal (3–8 minutes). In certain diseases – HAEMOPHILIA, for example – clotting time is greatly extended and the danger of serious haemorrhage enhanced.... coagulation
In autoimmune disorders, disease is due to damage wrought by circulating ANTIBODIES or sensitised lymphocytes (see LYMPHOCYTE). If the disease is due to circulating humoral antibodies, removal of these antibodies from the body should theoretically relieve the disorder. This is the principle on which plasma exchange was used in the management of autoimmune diseases due to circulating antibodies. Such disorders include Goodpasture’s syndrome, SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) and MYASTHENIA GRAVIS. One of the problems in the use of plasma exchange in the treatment of such diseases is that the body responds to the removal of an antibody from the circulation by enhanced production of that antibody by the immune system. It is therefore necessary to suppress this homeostatic response with cytotoxic drugs such as AZATHIOPRINE. Nevertheless, remissions can be achieved in autoimmune diseases due to circulating antibodies by the process of plasma exchange.... plasma exchange
– may be dried and in powder form kept almost inde?nitely; when wanted it is reconstituted by adding sterile distilled water. In powder form it can be transported easily and over long distances. Transfusion of plasma is especially useful in the treatment of SHOCK. One advantage of plasma transfusion is that it is not necessary to carry out testing of blood groups before using it.... plasma transfusion
Health Encyclopedia